Phosphorylated tau (p-Tau) biomarkers have become a cornerstone of Alzheimer’s disease research and diagnosis — but not all p-Tau species offer the same diagnostic or prognostic value. In this webinar, the featured speaker will explore the scientific rationale and clinical relevance of p-Tau 205 and 212, two emerging biomarkers showing promise for improving early detection and disease staging.
Through an in-depth discussion of the latest research, analytical validation data and potential clinical applications, this session will illuminate how p-Tau 205/212 may offer complementary insights to established markers like p-Tau 181 and 217 — and help move the field closer to scalable, blood-based Alzheimer’s diagnostics.
Whether working in biomarker discovery, translational research or clinical development, this webinar will offer actionable insights into the next wave of neurodegenerative disease biomarkers.
Register for this webinar to learn how p-Tau 205 and 212 may advance Alzheimer’s disease diagnosis and biomarker precision.
- Alzheimer's Disease ,
- asic Research ,
- Bioanalytical Testing ,
- Biomarkers ,
- Blood Biomarkers ,
- Central Nervous System ,
- Central Nervous System Diseases ,
- Clinical Research ,
- CNS ,
- Dementia ,
- Diagnostics ,
- Drug Development ,
- Neurodegenerative Disease ,
- Neurological Disorder ,
- Neurology ,
- Precision Medicine ,
- Tau ,
- Therapeutic Areas ,
- Translational Research
Speakers
Thomas K Karikari, PhD, Assistant Professor of Psychiatry, University of Pittsburgh
Dr. Thomas Karikari, PhD, is the Director of the Biofluid Biomarker Laboratory at the University of Pittsburgh, where he also leads the Mass Spectrometry and Single Molecule Array Biomarker Programs in the Department of Psychiatry. He heads the Fluid Biomarker Core of the NIA Alzheimer’s Program Project Grant. Internationally recognized, Dr. Karikari specializes in discovering, validating and implementing biofluid biomarkers for Alzheimer’s and related neurodegenerative diseases. His lab developed the first widely used plasma p-Tau 181 assay and immunoassays for p-Tau 212, p-Tau 217 and p-Tau 231, as well as a CNS-specific brain-derived Tau marker. The lab also created a streamlined method for quantifying plasma amyloid beta peptides via immunoprecipitation-mass spectrometry. These tools are widely applied in diagnostics and clinical trials. Dr. Karikari has extensive experience managing clinical labs and standardizing preanalytical procedures for biospecimen collection and analysis, with a focus on scalable protocols suitable for community-based and resource-limited settings.
Message Presenter
Wesley Straub, Vice President of Product Management, Quanterix
Wesley Straub obtained his BS in Chemistry magna cum laude from Boston University and a PhD from the University of California San Francisco. After working on the production, purification, and characterization of several biosimilars, recombinant blood factors, and novel biotherapeutics, he entered the life science technology with Forte Bio. Wesley has contributed to the development and launch of over 25 hardware, software, and reagent products across biolayer interferometry, capillary sequencing, qPCR, and Simoa technologies.
Message PresenterWho Should Attend?
This webinar is relevant to individuals interested in p-Tau biomarkers, Alzheimer’s pathology, early detection tools, disease staging and emerging blood-based diagnostics. Primary audience includes academic, pharma, CRO and clinical professionals involved in neurodegenerative disease research, biomarker development and CNS diagnostics. Specific job titles and areas of interest include:
- Neuroscientists, Neurobiologists and Neuropathologists
- Biomarker Discovery Scientists and Translational Researchers
- Clinical Researchers and Neurologists working in Alzheimer’s and dementia
- R&D professionals in pharmaceutical and biotech companies focused on CNS
- Lab Directors, Principal Investigators and Assay Development Scientists
- Diagnostic Developers, Medical Affairs and precision medicine stakeholders
What You Will Learn
Attendees will:
- Understand the biological relevance and phosphorylation dynamics of p-Tau 205 and 212 in the context of Alzheimer’s pathology
- Learn how these markers compare with and complement existing p-Tau biomarkers such as p-Tau 181 and 217
- Review new data on ultra-sensitive detection of p-Tau 205 and 212
- Gain insights into the potential clinical utility of p-Tau 205 and 212 in early diagnosis, disease staging and differentiation from other dementias
- Explore the future of blood-based biomarkers in Alzheimer’s disease
Xtalks Partner
Quanterix
Quanterix is a global leader in ultra-sensitive biomarker detection, enabling breakthroughs in disease research, diagnostics, and drug development. Its proprietary Simoa® technology delivers industry-leading sensitivity, allowing researchers to detect and quantify biomarkers in blood and other fluids at concentrations far below traditional limits. With more than 3,400 peer-reviewed publications, Quanterix has been a trusted partner to the scientific community for nearly two decades. In 2025, Quanterix acquired Akoya Biosciences, The Spatial Biology Company®, adding multiplexed tissue imaging with single-cell resolution to its portfolio and 1,396 installed instruments. Together, the combined company offers a uniquely integrated platform that connects biology across blood and tissue—advancing precision medicine from discovery to diagnostics. Learn more at www.quanterix.com.
You Must Login To Register for this Free Webinar
Already have an account? LOGIN HERE. If you don’t have an account you need to create a free account.
Create Account